Answers are grounded in this paper and cite their sources.
The first-generation autologous chondrocyte implantation (ACI-P) described by Peterson and colleagues used a periosteal patch to form a watertight cover over the articular cartilage defect, under which the autologous chondrocyte suspension was injected. Although good to excellent outcomes were often seen in >80% of patients and the durability of the repair documented up to 20 years, the procedure was noted to have a high rate of subsequent surgical procedures, most often for arthroscopic debridement of periosteal hypertrophy or incomplete incorporation. Consequently, the surgical technique advanced to use a porcine-derived bilayer of type I/III collagen with a porous layer that favors cell attachment and a smooth, compact layer that is cell occlusive. In use of the collagen membrane ACI, prospective studies have shown no diminution in clinical results and a marked reduction in subsequent surgeries from graft hypertrophy to <3%. Use of the collage membrane for ACI-C in the United States is currently an off-label use of an FDA-approved membrane, which should be discussed with the patient before surgery.
No takes yet. Share an insight, caveat, or question.
Gillogly et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: